Omnitus, 0.8 mg/ml syrup 200 ml

Pharmacodynamics Butamirate, the active ingredient of Omnitus®, is an anti-cough agent of central action. It is neither chemically nor pharmacologically related to opium alkaloids. It is not addictive or addictive. Suppresses cough by having a direct effect on the coughing center. It has a bronchodilator effect (dilates the bronchi). Helps ease breathing, improving spirometry (reduces airway resistance) and blood oxygenation (saturates blood with oxygen). Pharmacokinetics Absorption is high. After oral syrup administration with a dose containing 150 mg of butamirate citrate, maximum plasma concentration of the main metabolite (2-phenyl butyric acid) is reached after 1.5 hours and is 6.4 µg/ml. Hydrolysis of butamyrate, initially to 2-phenyl butyric acid and diethylaminoethoxyethanol, begins in plasma. These metabolites also have antitussive activity and, like butamirate, are largely (about 95%) bound to plasma proteins, which determines their long elimination half-life. 2-phenyl butyric acid is partially metabolized by hydroxylation at para-position. No cumulation is observed when taking the drug again. The elimination half-life is 6 hours. Excretion of the three metabolites occurs mainly through the kidneys; after conjugation in the liver, the acidic metabolites are largely bound to glucuronic acid.

Indications

Active ingredient

Composition

How to take, the dosage

Special Instructions

Synopsis

Contraindications

Side effects

Overdose

Symptoms: nausea, vomiting, drowsiness, diarrhea, dizziness, decreased blood pressure.

Treatment: orally – activated charcoal, saline laxatives, if necessary – symptomatic therapy.

Pregnancy use

Contraindicated in lactation, first trimester of pregnancy, children and adolescents under 3 years of age.

Similarities